Recurrent Urinary Tract Infection in Adults in Latvia: 2014 Observational Study

Vladimirs Strazdins1 and Harijs Cernevskis2
1Nephrologist, Medical Society Gailezers, Ltd., Riga, Latvia
2Nephrologist, P. Stradins University Hospital, Riga, Latvia

Abstract
Antimicrobial resistance is a growing worldwide problem. Urinary tract infection (UTI) is not an exception. Therefore, it is crucial to regularly update the bacterial flora spectrum data and the efficacy of the recommended empiric treatment to make timely and appropriate amendments where necessary.

This observational study was comprised in July-November 2014, when family physicians across Latvia submitted the anonymous patient data on recurrent UTI treatment in their practice. Anonymous patients’ electronic data files were received, 113 of those met the inclusion criteria and were further analyzed.

Bacterial flora spectrum in Latvian adult recurrent UTI population was fairly consistent with data from other European countries, with Escherichia coli identified in 66 (58.41%) cultures, of those as monoculture in 55 (58.51%) and as combined culture in 11 (11.70%) cases. Combined cultures without Escherichia coli were obtained in 28 (29.79%) cases.

Sensitivity against Nitrofuran derivatives (NFDs) was present in 88 cases (91.49% of total cultures); Escherichia coli resistance against NFDs was found in only 4 cases (6.06% of Escherichia coli cultures).

The current first-choice empiric treatment of recurrent UTI by NFDs may stay unchanged. Particular NFD used in Latvia (Furamags®) is safe, well-tolerated and effective first-line UTI treatment choice.

Keywords: Urinary tract infection; Adults; Nitrofuran derivates; Furamags; Recurrent UTI; Escherichia coli; Resistance

Background
Antimicrobial resistance is a growing worldwide problem. Urinary tract infection (UTI) is not an exception – according to European data, resistant Escherichia coli strains annually account to 32.500 cases with 5,100 deaths and 358,000 hospitalization days [1].

Therefore, it is crucial to regularly update the bacterial flora spectrum data and the efficacy of the recommended empiric treatment to make timely and appropriate amendments where necessary.

In Latvia, the novel nitrofuran derivate (NFD) is used as a standard empiric first-choice treatment for UTI (Furamags®).

NFDs are well-reputed as effective in low concentrations and against resistant bacteria; resistance against NFDs develops slowly and never reaches high degree; NFDs have wide activity range and are commonly used in treating urinary tract infections (UTI) both in adults and children.

First NFD were synthesized more than 60 years ago and were effectively used for treating UTI since then. However, those have side-effects, including frequent gastrointestinal disturbances, which effectively reduced NFD use especially in pediatrics.

NFDs act due to their specific furan aromatic ring, thus all NFDs has identical antimicrobial activity (but not identical bioavailability) [2,3]. The cross-resistance of NFDs is well-known and proved [4,5]. This allows the use of commercially available standard NFDs diagnostic disks for all NFDs.

The novel NFD, Furamags® (Furaginum solubile = potassium N-(5’-nitro-2’-furalililiden)-1-aminojigandantoin with magnesium carbonate) was first synthesized in Latvia in 1979. When first tested clinically it showed no side effects, was three times less toxic than Nitrofurantoin, and at the same time its bioavailability was three times higher than of Furazidin. Furamags® came commercially available in 1986 and since then became the first-line choice for empiric treatment of UTI both in adults and children in former socialist European states. Its use in pediatrics has been sufficiently explored earlier [6,7].

Objectives
Update the bacterial flora spectrum for recurrent UTI in Latvian adult population. Evaluate the efficacy of the currently recommended empiric UTI treatment.

Study Design
The study was comprised in July-November 2014, when family physicians across Latvia were asked to submit the anonymous patient data on recurrent UTI treatment in their practice. During the above period, anonymous patients’ electronic data files were received and analyzed.

The data were extracted and recorded as follows:
First visit: age and sex documentation; complaints documentation; obtaining and documenting urinalysis; obtaining and documenting urine culture (clean catch); empiric treatment initiation with Furamags® 50 mg twice daily, continued towards the second visit with a minimum of a seven full days.

Second visit after a minimum of a seven full days: complaints...
documentation; obtaining and documenting urinalysis; side effects documentation.

Inclusion Criteria
Anonymous outpatient medical records; patients' age over 18 years; patients with recurrent UTI defined as three UTI episodes per year or two UTI episodes with interval of 6 months or shorter. UTI was defined as a combination diagnosis based primarily on complains (symptoms) and confirmed by positive laboratory tests (urinalysis and/or culture) as further described.

Methods and Documentation
Complans were documented as: disuria (present/absent); flank, abdominal or back pain (present/absent); fever (present/absent).

Urirnalysis was documented: WBC count below 25 WBC/mcl as negative; proteinuria with values below 0.25 g/l as negative; nitrite test results as positive/negative; pH within values 5 to 7 as normal.

Urine cultures (BACTEC system) were documented as: positive/no growth; flora identification; CFU count, where values 5×10^4 and above accounted as positive; flora sensitivity against NFD (sensitive/resistant), using standard commercially available Nitrofurantoin disks.

Side effects were documented as: any gastrointestinal disturbance (present/absent); photosensibilisation, including rash (present/absent); other (present/absent) with details, if present.

McNemar’ test was used for evaluating categorical variables. IBM SPSS software (v.21) was used for data analysis.

Results
113 medical files were found consistent with inclusion criteria and further analyzed. Females were represented in 103 cases (91.15%), males in 10 cases (8.85%). Age varied from 19 to 87 years.

First visit: dysuria was present in 107 (94.69%) cases; pain was present in 77 (68.14%) cases; fewer were present in 29 (25.66%) cases. First urinanalysis showed WBC count over 25 WBC/mcl in 79 (69.91%) cases; proteinuria was positive in 19 (16.81%) cases; nitrite test was positive in 52 (46.02%) cases; pH within normal range was in 102 (90.27%) cases.

Second visit: dysuria was present in 6 (5.31%) cases; pain was present in 4 (3.54%) cases; fewer was absent in all cases.

Second urinanalysis showed WBC count over 25 WBC/mcl in 11 (10.58%) cases; proteinuria was positive in 1 (0.96%) case; nitrite test was positive in 8 (7.69%) cases; pH within normal range was in 94 (90.38%) cases.

Cultures were positive in 94 (83.19%) cases, no growth found in 19 (16.81%) cases. Escherichia coli was identified in 66 (58.41%) cultures, of those as monoculture in 55 (58.51%) and as combined culture in 11 (11.70%) cases. Combined cultures without Escherichia coli were obtained in 28 (29.79%) cases.

Other flora was represented by: KES group (Klebsiella, Enterobacter, Serratia) in 13 (11.50%); Morganella morgani in 1 (0.88%); coagulase-negative Staphylococcus in 6 (5.31%); Bacillus sp. in 4 (3.54%); Streptococcus sp. in 4 (3.54%); B group Beta-hemolytic Streptococcus in 2 (1.77%); Staphylococcus aureus in 3 (2.65%); Proteus sp. in 4 (3.54%); Enterococcus sp. in 11 (9.73%); Providencia rettgeri in 1 (0.88%); and Staphylococcus Saprophyticus in 3 (2.65%) cases.

CFU count was positive (5×10^4 and over) in 77 (68.14%) cases. Sensitivity against NFDs was present in 88 cases (91.49% of total cultures), Escherichia coli resistance against NFDs was found in only 4 cases (6.06% of Escherichia coli cultures).

Side effects: minor digestive-related complaints not requiring Furamag® discontinuation were recorded in 2 (1.77%) cases; no photosensibilisation or other side effects were recorded.

Discussion
No incidence and prevalence data could be obtained due to study limitations, but published data list UTI among major healthcare problems, causing over 7 million of doctor visits annually [8] and 15% of all prescribed antibiotics in USA alone [9].

Globally, an estimated 150 million UTIs occur annually, resulting in over six billion dollars in direct healthcare expenditures. Predicted risk factors for UTI in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), and a 10-year epidemiological forecast the increase of UTI incident cases with E. coli as most prevalent causative pathogen [10].

The concern of developing resistance to first-line antimicrobial agents, including fluoroquinolones, has become increasingly common in Escherichia coli [11]. The most recent European data suggest the avoidance of currently widely recommended fluoroquinolones, co-trimoxazole, or cephalosporins, and places nitrofuran derivates and fosfomycin as first-choice antibiotics for the treatment of uncomplicated community-acquired cystitis [12,13].

Therefore, it is crucial to regularly update the bacterial flora spectrum data and the efficacy of the locally recommended empiric treatment to make timely and appropriate amendments where necessary.

Bacterial flora spectrum in Latvian adult recurrent UTI population showed no surprises and was fairly consistent with data even from geographically apart-standing regions, with Escherichia coli as a prevalent flora [14-17].

Nitrofurantoin derivate, in Latvian case Furamags® in particular, was clinically effective in all cases, even in those where culture was recorded as NFD-resistant. There was not a single case without any improvement in controlled parameters – Furamag® was clinically effective in all cases. This confirms unique multifactorial antibacterial activities of NFDs, which simultaneously inhibit protein synthesis, aerobic energy metabolism, DNA synthesis, RNA synthesis and cell-wall synthesis, thus ensuring antibacterial activity even against the seemingly resistant flora [18,19].

Furamags® tolerance was excellent, resulting only in 2 (1.77%) mild gastrointestinal events (not requiring the treatment discontinuation), which is fully comparable with earlier pediatric studies where side effect rate was even lower (1.2%). In comparison, up to 34% gastrointestinal intolerance for the Nitrofurantoin crystalline form and up to 13% for the Nitrofurantoin macrocrystalline form was reported [20].

Conclusions
UTI patterns in Latvia are similar to those of other European countries.

The current first-choice empiric treatment may stay unchanged.

Furamags® is safe, well-tolerated and effective first-line UTI treatment choice, where available.
Acknowledgements

The authors wish to thank all participating family physicians for providing access to their patient data and fine cooperation during the data collection. Special thanks to JSC “Olainfarm” for providing technical assistance in data collection.

References

1. European Centre for Disease Prevention and Control (ECDC) and European Medicines Agency (EMEA). ECDC/EMEA Joint Technical Report (2009) The bacterial challenge: time to react. Stockholm.
2. Grunberg E, Tisworth EH (1973) Chemotherapeutic properties of heterocyclic compounds: monocyclic compounds with five-membered rings. Annu Rev Microbiol 27: 317-346.
3. Raether W, Hanel H (2003) Nitroheterocyclic drugs with broad spectrum activity. Parasitol Res 51: S19-S39.
4. McCalla DR (1965) Nitrofurans Derivatives As Radiomimetic Agents: Cross-Resistance Studies With Escherichia coli. Can J Microbiol 11: 185-191.
5. Obaseiki-Ebor EE, Breeze AS (1984) Gentamicin- and neomycin-resistant mutants of Escherichia coli K-12 cross-resistant to nitrofurans. J Antimicrob Chemother 13: 567-576.
6. Strazdins V (2004) Nitrofuran derivate use experience in pediatric nephrology. Journal "Doctus" Riga. [article in Latvian]
7. Strazdins V, Andersone I (2006) New nitrofuran derivate in UTI: 5-year pediatric experience. Pediatr Nephrol 21: 1163-1165.
8. Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113 Suppl 1A: S5-S135.
9. Mazzulli T (2002) Resistance trends in urinary tract pathogens and impact on management. J Urol 168(4 Pt 2): 1720-1722.
10. EpiCast Report Gram-Negative Bacterial Urinary Tract Infection – Epidemiology Forecast to 2022. GlobalData.
11. Bader MS, Hawkoldt J, Brooks A (2010) Management of complicated urinary tract infections in the era of antimicrobial resistance. Postgrad Med 122: 7-15.
12. Sorolzano A, Jimenez-Pacheco A, de Dios Luna del Castillo J, Sampedro A, et al. (2014) Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: A 7-year surveillance study. Am J Infect Control 42: 1033-1038.
13. Kresken M, Pfeifer I, Hafner D, Wresch R, Körber-Irgang B (2014) Occurrence of multidrug resistance to oral antibiotics among Escherichia coli urine isolates from outpatient departments in Germany: Extended-spectrum β-lactamas and the role of fosfomycin. Int J Antimicrob Ag 44: 295-300.
14. Kodner CM, Thomas Gupton EK (2010) Thomas Gupton. Recurrent Urinary Tract Infections in Women: Diagnosis and Management. Am Fam Physician 82: 638-643.
15. Annette Epp, Annick Larochelle (2010) SOCG Clinical Practice Guideline on Recurrent Urinary Tract Infection. JGGC 250.
16. Antonella Agodi, Martina Barchitta (2011) Epidemiology and Control of Urinary Tract Infections in Intensive Care Patients. University of Catania Italy.
17. Jackson C (2013) Urinary Tract Infection in Adults. Patient.
18. McOsker CC, Fitzpatrick PM (1994) Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother 33 Suppl A: 23-30.
19. Sandegren L, Lindqvist A, Kahlmeter G, Andersson DI (2008) Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother 62: 495-503.
20. ***http://www.drugs.com/sfx/macrobid-side-effects.html